PUBLISHER: Grand View Research | PRODUCT CODE: 1405753
PUBLISHER: Grand View Research | PRODUCT CODE: 1405753
The global patient-controlled analgesic pumps market size is expected to reach USD 656.5 million by 2030, registering a CAGR of 5.9% from 2023 to 2030, according to a new report by Grand View Research, Inc. Patient-controlled Analgesic (PCA) pumps offer several advantages including fewer post-operative complications, improved quality of recovery, less sedation, and minimal use of medication. Also, PCA pumps are useful among patients that have a problem in taking oral medications. Thus, the rising adoption of the medical device among patients that are unable to take oral medications is expected to drive the market. In addition, the growing trend of home healthcare during the COVID-19 pandemic is also expected to propel market growth in the coming years.
Patient-controlled analgesic pumps have positive outcomes for the pediatric postsurgical population including increasing autonomy, simplifying pain relief in the postoperative period, and maintaining stable hemodynamics. Innovative PCA techniques such as PCRA, PCEA, and noninvasive forms of PCA have extended the options available for pain treatment and are estimated to have a positive impact on market growth. Advances in the pumps including variable-rate infusions that are calculated based on patient needs for analgesic along with improved patient monitoring are anticipated to enhance the use of such techniques during the forecast timeframe.
Rising cases of chronic pain disorders including cancer, rheumatoid arthritis, and fibromyalgia are anticipated to boost the market growth. For instance, as per the CDC, in 2019 around 20.4% of adults had chronic pain. Chronic pain increases with age and is highest among adults aged 65 and above. Hence, the rising occurrence of chronic pain among adults is anticipated to create robust growth opportunities in the market.